Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Impax Laboratories Inc (NASDAQ:IPXL)

12.05
Delayed Data
As of Jan 19
 -0.35 / -2.82%
Today’s Change
11.88
Today|||52-Week Range
40.74
-9.06%
Year-to-Date
EpiPen Competitor, Auvi-Q, Will Hit the Market in February
Jan 19 / TheStreet.com - Paid Partner Content
Biotech Premarket Movers: SGMO, IPXL, PTLA
Jan 13 / TheStreet.com - Paid Partner Content
Is Impax a Great Stock for Value Investors?
Jan 19 / Zacks.com - Paid Partner Content
Stock Market Roundup, Jan. 12: AMZN Jobs, FCAU Cheating, AKS & X Tank
Jan 12 / Zacks.com - Paid Partner Content
Assembly Biosciences (ASMB) Looks Good: Stock Up 13.9%
Jan 18 / Zacks.com - Paid Partner Content
CVS Debuts Cheap EpiPen Alternative
Jan 12 / Zacks.com - Paid Partner Content
Examining Volkswagen and Fiat Chrysler's Emissions Cheating Scandals
Jan 13 / Zacks.com - Paid Partner Content
CVS cuts cost for generic EpiPen competitor
Jan 12 / CNNMoney.com
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlig...
Jan 13 / Zacks.com - Paid Partner Content
Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases
Jan 11 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close12.40
Today’s open12.40
Day’s range12.05 - 12.40
Volume946,137
Average volume (3 months)1,288,487
Market cap$916.0M
Dividend yield--
Data as of 4:00pm ET, 01/19/2017

Growth & Valuation

Earnings growth (last year)-33.33%
Earnings growth (this year)-20.01%
Earnings growth (next 5 years)+5.00%
Revenue growth (last year)+44.36%
P/E ratioNM
Price/Sales3.58
Price/Book0.85

Competitors

 Today’s
change
Today’s
% change
INSMInsmed Inc0.000.00%
CLCDCoLucid Pharmaceutic...+0.05+0.11%
AIMTAimmune Therapeutics...-0.36-1.86%
ACORAcorda Therapeutics ...-0.40-1.90%
Data as of 4:00pm ET, 01/19/2017

Financials

Next reporting dateFebruary 28, 2017
EPS forecast (this quarter)$0.15
Annual revenue (last year)$860.5M
Annual profit (last year)$39.0M
Net profit margin4.53%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President, Chief Executive Officer &
Director
J. Kevin Buchi
Senior Vice President-
Global Operations
Andrew Schaschl
Corporate headquarters
Hayward, California

Forecasts


Search for Jobs